Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. 2006

Shaoyong Chen, and Youyuan Xu, and Xin Yuan, and Glenn J Bubley, and Steven P Balk
Hematology-Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA.

Androgen receptors (ARs) are phosphorylated at multiple sites in response to ligand binding, but the kinases mediating AR phosphorylation and the importance of these kinases in AR function have not been established. Here we show that cyclin-dependent kinase 1 (Cdk1) mediates AR phosphorylation at Ser-81 and increases AR protein expression, and that Cdk1 inhibitors decrease AR Ser-81 phosphorylation, protein expression, and transcriptional activity in prostate cancer (PCa) cells. The decline in AR protein expression mediated by the Cdk inhibitor roscovitine was prevented by proteosome inhibitors, indicating that Cdk1 stabilizes AR protein, although roscovitine also decreased AR message levels. Analysis of an S81A AR mutant demonstrated that this site is not required for transcriptional activity or Cdk1-mediated AR stabilization in transfected cells. The AR is active and seems to be stabilized by low levels of androgen in "androgen-independent" PCas that relapse subsequent to androgen-deprivation therapy. Significantly, the expression of cyclin B and Cdk1 was increased in these tumors, and treatment with roscovitine abrogated responses to low levels of androgen in the androgen-independent C4-2 PCa cell line. Taken together, these findings identify Cdk1 as a Ser-81 kinase and indicate that Cdk1 stabilizes AR protein by phosphorylation at a site(s) distinct from Ser-81. Moreover, these results indicate that increased Cdk1 activity is a mechanism for increasing AR expression and stability in response to low androgen levels in androgen-independent PCas, and that Cdk1 antagonists may enhance responses to androgen-deprivation therapy.

UI MeSH Term Description Entries
D008297 Male Males
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D010768 Phosphoserine The phosphoric acid ester of serine. Serine Phosphate,Phosphorylserine,Seryl Phosphate,Phosphate, Serine,Phosphate, Seryl
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D011687 Purines A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
D011944 Receptors, Androgen Proteins, generally found in the CYTOPLASM, that specifically bind ANDROGENS and mediate their cellular actions. The complex of the androgen and receptor migrates to the CELL NUCLEUS where it induces transcription of specific segments of DNA. Androgen Receptors,5 alpha-Dihydrotestosterone Receptor,Androgen Receptor,Dihydrotestosterone Receptors,Receptor, Testosterone,Receptors, Androgens,Receptors, Dihydrotestosterone,Receptors, Stanolone,Stanolone Receptor,Testosterone Receptor,5 alpha Dihydrotestosterone Receptor,Androgens Receptors,Receptor, 5 alpha-Dihydrotestosterone,Receptor, Androgen,Receptor, Stanolone,Stanolone Receptors,alpha-Dihydrotestosterone Receptor, 5
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077546 Roscovitine A purine derivative and competitive inhibitor of CYCLIN-DEPENDENT KINASES that has therapeutic potential as an antineoplastic and antiviral agent. (2R)-2-((6-Benzylamino-9-(propan-2-yl)-9H-purin-2-yl)amino)butan-1-ol,2-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine,CYC 202,CYC-202,CYC202,R-roscovitine,Seliciclib,R roscovitine
D000728 Androgens Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. Androgen,Androgen Receptor Agonist,Androgen Effect,Androgen Effects,Androgen Receptor Agonists,Androgenic Agents,Androgenic Compounds,Agents, Androgenic,Agonist, Androgen Receptor,Agonists, Androgen Receptor,Compounds, Androgenic,Effect, Androgen,Effects, Androgen,Receptor Agonist, Androgen,Receptor Agonists, Androgen
D014158 Transcription, Genetic The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION. Genetic Transcription

Related Publications

Shaoyong Chen, and Youyuan Xu, and Xin Yuan, and Glenn J Bubley, and Steven P Balk
September 2011, The Journal of biological chemistry,
Shaoyong Chen, and Youyuan Xu, and Xin Yuan, and Glenn J Bubley, and Steven P Balk
October 2013, American journal of physiology. Endocrinology and metabolism,
Shaoyong Chen, and Youyuan Xu, and Xin Yuan, and Glenn J Bubley, and Steven P Balk
January 2001, Journal of andrology,
Shaoyong Chen, and Youyuan Xu, and Xin Yuan, and Glenn J Bubley, and Steven P Balk
July 1999, Molecular and cellular biology,
Shaoyong Chen, and Youyuan Xu, and Xin Yuan, and Glenn J Bubley, and Steven P Balk
July 2007, The Journal of biological chemistry,
Shaoyong Chen, and Youyuan Xu, and Xin Yuan, and Glenn J Bubley, and Steven P Balk
April 2005, Proceedings of the National Academy of Sciences of the United States of America,
Shaoyong Chen, and Youyuan Xu, and Xin Yuan, and Glenn J Bubley, and Steven P Balk
June 2009, Cancer letters,
Shaoyong Chen, and Youyuan Xu, and Xin Yuan, and Glenn J Bubley, and Steven P Balk
August 2016, Oncotarget,
Shaoyong Chen, and Youyuan Xu, and Xin Yuan, and Glenn J Bubley, and Steven P Balk
September 2018, The New England journal of medicine,
Shaoyong Chen, and Youyuan Xu, and Xin Yuan, and Glenn J Bubley, and Steven P Balk
May 2008, Oncogene,
Copied contents to your clipboard!